Labcorp extends relationship with the Department of Defense to provide laboratory services
Burlington, NC – February 16, 2021 – Labcorp (NYSE: LH), a leading global life sciences company, has extended its agreement with the U.S. Department of Defense to provide clinical reference laboratory services to U.S. military personnel and dependents across the globe.
Labcorp Diagnostics will provide reference lab testing services, supplies, required courier/ logistics services and dedicated on-site resources to Army, Air Force, Coast Guard, and Navy Military Testing Facilities in the U. S. and around the world in support of the renewed agreement.
“Labcorp is proud to support the Department of Defense, its medical professionals, and its service men and women with our clinical reference laboratory services,” said Bryan Vaughn, senior vice president, hospitals and health systems, Labcorp Diagnostics. “We have partnered with the Department of Defense for the past 7 years and look forward to continuing to build upon that relationship.”
,
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and save lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to scientific collaborations, customer contracts and relationships, the anticipated benefits of such collaboration and relationships, and the expected impact that the various collaborations and customer relationships may have on the Company’s financial results. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, the Company’s ability to establish and maintain strategic partnerships and other scientific collaborations, competitive actions in the marketplace, and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, adverse actions of governmental and other third-party payers, patient safety issues, changes in testing guidelines or recommendations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.
# # #
LabCorp Contacts:
Media: Christopher Allman-Bradshaw - 336-436-8263
[email protected]
Investors: Clarissa Willett - 336-436-5076
[email protected]
Source: Labcorp